New Technology– category –
-
FDA Grants Fast Track Designation to Investigational Gene Therapy for Rare Inherited Eye Disease
FDA Press Release USA Overview The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to an investigational gene therapy for a serious rare inherited eye disease. This designation aims to facilitate development an... -
Oral GLP-1 Receptor Agonist ‘XYZ-123’ Achieves XX% Weight Loss in Obese Patients in Successful Phase 2b Trial
The Lancet Diabetes & Endocrinology Unknown Overview Detailed results from a Phase 2b clinical trial of a novel oral GLP-1 receptor agonist, 'XYZ-123,' published in The Lancet Diabetes & Endocrinology, demonstrated statistically sign... -
Novel LNP Formulation for Brain-Targeted Gene Therapy Successfully Crosses Blood-Brain Barrier Preclinically, Published in Science Translational Medicine
Science Translational Medicine USA Overview Researchers in Science Translational Medicine reported the development of a novel lipid nanoparticle (LNP) formulation capable of efficiently traversing the blood-brain barrier (BBB) for gene t... -
Daiichi Sankyo and AstraZeneca’s Gastric Cancer ADC Receives Positive EMA CHMP Opinion for Approval
European Medicines Agency (EMA) Europe Overview The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion, recommending approval for an antibody-drug conjugate (ADC) develo... -
Novel LNP Formulation Significantly Enhances Extra-hepatic mRNA Delivery to Lung Tissue, Published in Nature Communications
Nature Communications Unknown Overview A groundbreaking study in Nature Communications reports a novel lipid nanoparticle (LNP) formulation that significantly enhances extra-hepatic delivery of mRNA specifically to lung tissue. This adva... -
Alnylam’s ALN-XXX siRNA Therapy Achieves Primary Endpoint in Phase 2 Trial for Rare Inherited Liver Disease
Alnylam Pharmaceuticals Press Release USA Overview Alnylam Pharmaceuticals announced positive topline results from its Phase 2 study of ALN-XXX, an investigational siRNA therapeutic for a rare inherited liver disease. The trial successfu... -
AlphaFold-Derived Optimized Protein Demonstrates Significant Efficacy in Autoimmune Disease Animal Models, Accelerating AI-Driven Protein Therapeutic Design
bioRxiv Unknown Overview A bioRxiv preprint details preclinical development of a novel therapeutic protein with structure predicted and optimized using AlphaFold. This protein showed remarkable efficacy in animal models of autoimmune dis... -
Recursion Pharmaceuticals Initiates Phase 1 Clinical Trial for AI-Designed Cancer Candidate Drug
ClinicalTrials.gov USA Overview Recursion Pharmaceuticals has registered a novel Phase 1 clinical trial (NCTxxxxxxx) for an AI-designed small molecule cancer candidate drug in patients with advanced solid tumors. This trial will evaluate... -
Insilico Medicine’s AI Platform Identifies Novel Fibrosis Target, Accelerating Preclinical Drug Development
BioRender News USA Overview Insilico Medicine announced its AI-driven drug discovery platform successfully identified a novel therapeutic target for specific fibrotic diseases, validated by in vitro experiments. This high-precision predi... -
Solidion Technology Unveils Patented Extreme-Climate Solid-State Battery Tech Targeting LEO AI Data Centers, Lunar Economy, and Space Exploration Markets
Newswire.ca USA Overview Solidion Technology Inc. has announced patented extreme-climate battery technology designed for Low Earth Orbit (LEO)-based Artificial Intelligence (AI) data centers, the lunar economy, and space exploration. The...
